# The Next Generation of the GLP-1 Revolution Is Already Underway

- URL: https://theranews.net/blog/2026-05-12-the-next-generation-of-the-glp-1-revolution-is-already-underway-74601c/
- Published: 2026-05-12
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: financialcontent
- Original report: https://www.financialcontent.com/article/gnwcq-2026-5-11-the-next-generation-of-the-glp-1-revolution-is-already-underway
- Topics: mental-health
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating h

---
The GLP-1 market continues to expand rapidly as pharmaceutical companies develop next-generation therapies. Originally created for blood glucose regulation in diabetes patients, GLP-1 receptor agonists are now widely recognized for their ability to produce meaningful weight loss and improve broader metabolic outcomes. JPMorgan Chase & Co. projects the broader obesity drug market could approach $200 billion by 2030 as adoption expands globally. Estimates suggest that anywhere from 25 to 30 million Americans could be using GLP-1 therapies by 2030, compared with approximately 10 million users in 2026.

## Next-Generation Approaches

While market leaders Novo Nordisk and Eli Lilly dominate through injectable products, the industry is shifting toward next-generation incretin therapies focused on improving efficacy, tolerability, and convenience. Oral formulations, expanded indications, and combination metabolic therapies are becoming major priorities. Morgan Stanley projects the global GLP-1 market could approach $190 billion by 2035 as patient adoption expands and broader therapeutic applications emerge. IQVIA describes 2026 as potentially becoming the "year of the orals," with oral GLP-1 formulations expected to significantly improve accessibility, adherence, and long-term maintenance therapy adoption.

SureNano Science is advancing GEP-44, a patented triple agonist peptide that targets GLP-1 and peptide YY receptors, designed to improve efficacy and tolerability compared to first-generation GLP-1 drugs. In preclinical testing, GEP-44 produced approximately 15% weight loss compared with roughly 9% observed with liraglutide, while food intake reductions approached 39% versus approximately 20% for the comparator. The compound reportedly avoided nausea and vomiting, common side effects with current therapies.

## Recent Regulatory Advances

Eli Lilly announced FDA approval of Foundayo (orforglipron) for adults with obesity. Novo Nordisk announced that oral Ozempic tablets (semaglutide) 1.5 mg, 4 mg, and 9 mg will be available for adults with type 2 diabetes. Pfizer reported positive results from its VESPER-3 study investigating monthly maintenance dosing of PF-3944, showing patients could maintain efficacy while reducing dosing frequency fourfold.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.financialcontent.com/article/gnwcq-2026-5-11-the-next-generation-of-the-glp-1-revolution-is-already-underway](https://www.financialcontent.com/article/gnwcq-2026-5-11-the-next-generation-of-the-glp-1-revolution-is-already-underway)*